BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 33308378)

  • 1. Antitumor Activity of Lipid-DNA Aptamer Modified T Lymphocytes in Carcinoma.
    Zhong L; Gan L; Deng Z; Liu X; Peng H; Tang H; Liu X; Fang F; Yao F; Li W; Liu Z; Hou W; Cui C; Zhao Y; Tan W; Shi W; He J
    J Biomed Nanotechnol; 2020 Jul; 16(7):1110-1118. PubMed ID: 33308378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aptamer-SH2 superbinder-based targeted therapy for pancreatic ductal adenocarcinoma.
    Liu AD; Zhou J; Bi XY; Hou GQ; Li SS; Chen Q; Xu H; Cao X
    Clin Transl Med; 2021 Mar; 11(3):e337. PubMed ID: 33783993
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA Aptamer Selected against Pancreatic Ductal Adenocarcinoma for in vivo Imaging and Clinical Tissue Recognition.
    Wu X; Zhao Z; Bai H; Fu T; Yang C; Hu X; Liu Q; Champanhac C; Teng IT; Ye M; Tan W
    Theranostics; 2015; 5(9):985-94. PubMed ID: 26155314
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted Delivery of C/EBPα -saRNA by Pancreatic Ductal Adenocarcinoma-specific RNA Aptamers Inhibits Tumor Growth In Vivo.
    Yoon S; Huang KW; Reebye V; Mintz P; Tien YW; Lai HS; Sætrom P; Reccia I; Swiderski P; Armstrong B; Jozwiak A; Spalding D; Jiao L; Habib N; Rossi JJ
    Mol Ther; 2016 Jun; 24(6):1106-1116. PubMed ID: 26983359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cholecystokinin B Receptor-Specific DNA Aptamer for Targeting Pancreatic Ductal Adenocarcinoma.
    Clawson GA; Abraham T; Pan W; Tang X; Linton SS; McGovern CO; Loc WS; Smith JP; Butler PJ; Kester M; Adair JH; Matters GL
    Nucleic Acid Ther; 2017 Feb; 27(1):23-35. PubMed ID: 27754762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aptamers: a novel targeted theranostic platform for pancreatic ductal adenocarcinoma.
    Li Q; Maier SH; Li P; Peterhansl J; Belka C; Mayerle J; Mahajan UM
    Radiat Oncol; 2020 Aug; 15(1):189. PubMed ID: 32758252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intraepithelial Attack Rather than Intratumorally Infiltration of CD8+T Lymphocytes is a Favorable Prognostic Indicator in Pancreatic Ductal Adenocarcinoma.
    Zhang J; Wang YF; Wu B; Zhong ZX; Wang KX; Yang LQ; Wang YQ; Li YQ; Gao J; Li ZS
    Curr Mol Med; 2017; 17(10):689-698. PubMed ID: 29521231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients.
    Oberg HH; Grage-Griebenow E; Adam-Klages S; Jerg E; Peipp M; Kellner C; Petrick D; Gonnermann D; Freitag-Wolf S; Röcken C; Sebens T; Vogel I; Becker T; Ebsen M; Kabelitz D; Wesch D; Sebens S
    Pancreatology; 2016; 16(6):1069-1079. PubMed ID: 27424476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a panel of DNA Aptamers with High Affinity for Pancreatic Ductal Adenocarcinoma.
    Champanhac C; Teng IT; Cansiz S; Zhang L; Wu X; Zhoa Z; Fu T; Tan W
    Sci Rep; 2015 Nov; 5():16788. PubMed ID: 26603187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elucidation and Structural Modeling of CD71 as a Molecular Target for Cell-Specific Aptamer Binding.
    Wu X; Liu H; Han D; Peng B; Zhang H; Zhang L; Li J; Liu J; Cui C; Fang S; Li M; Ye M; Tan W
    J Am Chem Soc; 2019 Jul; 141(27):10760-10769. PubMed ID: 31185171
    [TBL] [Abstract][Full Text] [Related]  

  • 11. X-aptamers targeting Thy-1 membrane glycoprotein in pancreatic ductal adenocarcinoma.
    Wang H; Li X; Lai LA; Brentnall TA; Dawson DW; Kelly KA; Chen R; Pan S
    Biochimie; 2021 Feb; 181():25-33. PubMed ID: 33242496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer.
    Pu N; Zhao G; Yin H; Li JA; Nuerxiati A; Wang D; Xu X; Kuang T; Jin D; Lou W; Wu W
    J Transl Med; 2018 Oct; 16(1):294. PubMed ID: 30359281
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3D-spheroids: What can they tell us about pancreatic ductal adenocarcinoma cell phenotype?
    Gagliano N; Sforza C; Sommariva M; Menon A; Conte V; Sartori P; Procacci P
    Exp Cell Res; 2017 Aug; 357(2):299-309. PubMed ID: 28571915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial.
    Beatty GL; O'Hara MH; Lacey SF; Torigian DA; Nazimuddin F; Chen F; Kulikovskaya IM; Soulen MC; McGarvey M; Nelson AM; Gladney WL; Levine BL; Melenhorst JJ; Plesa G; June CH
    Gastroenterology; 2018 Jul; 155(1):29-32. PubMed ID: 29567081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma.
    Raj D; Yang MH; Rodgers D; Hampton EN; Begum J; Mustafa A; Lorizio D; Garces I; Propper D; Kench JG; Kocher HM; Young TS; Aicher A; Heeschen C
    Gut; 2019 Jun; 68(6):1052-1064. PubMed ID: 30121627
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Perspectives in the treatment of pancreatic adenocarcinoma.
    Cid-Arregui A; Juarez V
    World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pancreatic tumor-specific biomarker characterized in humans and mice as an immunogenic onco-glycoprotein is efficient in dendritic cell vaccination.
    Collignon A; Perles-Barbacaru AT; Robert S; Silvy F; Martinez E; Crenon I; Germain S; Garcia S; Viola A; Lombardo D; Mas E; Béraud E
    Oncotarget; 2015 Sep; 6(27):23462-79. PubMed ID: 26405163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen.
    Cappello P; Tomaino B; Chiarle R; Ceruti P; Novarino A; Castagnoli C; Migliorini P; Perconti G; Giallongo A; Milella M; Monsurrò V; Barbi S; Scarpa A; Nisticò P; Giovarelli M; Novelli F
    Int J Cancer; 2009 Aug; 125(3):639-48. PubMed ID: 19425054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer.
    Mace TA; Shakya R; Pitarresi JR; Swanson B; McQuinn CW; Loftus S; Nordquist E; Cruz-Monserrate Z; Yu L; Young G; Zhong X; Zimmers TA; Ostrowski MC; Ludwig T; Bloomston M; Bekaii-Saab T; Lesinski GB
    Gut; 2018 Feb; 67(2):320-332. PubMed ID: 27797936
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.